Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
BSIM Therapeutics – Linkedin
BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that still represent unmet medical needs.
Our first products are directed against a rare and fatal pathology called Hereditary ATTR amyloidosis with Polyneuropathy (hATTR-PN), also known as Familial Amyloid Polyneuropathy (TTR-FAP). We are developing drug candidates that fit into different target-product profiles and thus enable the treatment of a broader range of hATTR-PN manifestations, including oculopathy (e.g. vitreous opacities, glaucoma) and central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia).
We are also working on development candidates for the treatment of TTR-related cardiomyopathies such as hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), also known as Familial Amyloid Cardiomyopathy (TTR-FAC), and wild-type ATTR amyloidosis (wtATTR), also known as Senile Systemic Amyloidosis (SSA).
myBinderRelated Content
-
Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL AmyloidosisProthena Corporation PLC, a clinical-sta...
-
Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropa...Alnylam Pharmaceuticals, Inc., the leadi...
-
FDA OKs Inotersen (Tegsedi) for Hereditary ATTR With PolyneuropathyThe US Food and Drug Administration (FDA...
-
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare a...Pfizer Inc. announced today that the U.S...
-
FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated AmyloidosisThe FDA announced that it has approved p...
-
Inotersen: An Exciting Prospect for hATTR Amyloidosis TreatmentA new hereditary ATTR (hATTR) amyloidosi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
